ClinicalTrials.gg
Not yet recruitingNCT07938216Updated Nov 16, 2026

Economic Evaluation of Three Categories of Drugs for Improving Cognitive Impairment in Alzheimer's Disease

An observational study in Alzheimer's Disease, sponsored by Shanghai Mental Health Center. Not yet recruiting. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Shanghai Mental Health Center · Observational

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
150
Ages
50 Years to 85 Years
Sex
All
01

Study summary

This observational study aims to understand the efficacy, adverse reactions and costs of three different drug mechanisms used to treat dementia in patients with Alzheimer's disease, over a period of 2 years.

Read the detailed description

Alzheimer's disease (AD) imposes a heavy disease burden. Pharmacoeconomic evaluation is crucial for the rational clinical use of drugs and the allocation of medical resources. Currently, the research and development of innovative drugs represented by Aβ-targeted monoclonal antibodies are in full swing. Although various drugs used to improve cognitive impairment in AD have significant therapeutic advantages in clinical practice, due to the different durations of their clinical applications, their economic benefits and risk assessments remain insufficient.

This study, based on decision tree models, integrates multi-source data to conduct multi-dimensional cost analyses of three categories of drugs and explores the influencing factors. The aim is to provide evidence for clinical medication and health insurance policy-making, fill the gap in the pharmacoeconomic research of new drugs, and promote the development of the AD treatment field.

02

Conditions studied

  • Alzheimer's Disease

Browse trials for

Keywords

  • pharmacoeconomics
  • alzheimer disease
  • cholinesterase inhibitors
  • Excitatory amino acid receptor antagonists
  • Non-competitive beta-amyloid (Aβ) antibodies
03

In context

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

This study's planned enrollment of 150 is below the median of 200 across 815 observational studies indexed under Alzheimer Disease.

Browse Alzheimer Disease studies →

Lead sponsor

Shanghai Mental Health Center is the lead sponsor of 274 studies on the registry; 93 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients aged 50-85 years with mild to moderate Alzheimer's disease-related cognitive impairment receiving continuous anti-dementia pharmacotherapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 50 to 85 years, of any gender
  • Clinical diagnosis of Alzheimer's disease, CDR-GS score 1 to 2 (mild to moderate stage)
  • Able to communicate and complete study rating scales independently
  • No other organic brain diseases
  • Complete clinical medical records available
  • Female participants: (≥24 weeks), surgically sterilized, or agree to effective ; women of with \<24 weeks post-menopause must have negative pregnancy test at screening
  • Continuous drug treatment for more than 18 months
  • Voluntary participation and signed form

Exclusion criteria

Exclusion Criteria:

  • Severe primary cardiac, hepatic, pulmonary, renal, hematological or other life-threatening diseases, or high suicide risk
  • Severe physical illnesses that may interfere with outcome assessment
  • Participants judged unsuitable for enrollment by investigators
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cholinergic group
  • Excitatory amino acid receptor antagonists group
  • Non-competitive β-amyloid protein group
06

What researchers measure

Primary outcomes

  1. Incremental Cost-Effectiveness Ratio

    Incremental cost-effectiveness ratio calculated across three drug groups for Alzheimer's disease cognitive impairment.

    Time frame: 2028.4

  2. Change in ADAS-Cog13

    Change from baseline in ADAS-Cog13 cognitive scores

    Time frame: 2028.4

  3. Proportion of Participants With Adverse Events

    proportion of participants with adverse events, compared across three drug groups.

    Time frame: 2028.4

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Apr 2028, 16 months later.

Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 16 months is below that.

Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2026
First posted
Nov 16, 2026
StartEst.
Dec 3, 2026
Primary completionEst.
Apr 30, 2028
CompletionEst.
May 30, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938216
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Dec 3, 2026 (estimated)
Primary completion
Apr 30, 2028 (estimated)
Completion
May 30, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Zhang jian ming, Master
Contact
"zhangjianming@smhc.org.cn
+8618017311232

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion